We are live on ! Find out more
ANAB icon

AnaptysBio

131 hedge funds and large institutions have $736M invested in AnaptysBio in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 52 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more capital inflows, than outflows

Capital inflows: $94.7M | Capital outflows: $36M

6.58% more ownership

Funds ownership: 100.88% → 107.46% (+6.6%)

4% less funds holding

Funds holding: 136 → 131 (-5)

24% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 21

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 52

Holders
131
Holders Change
-5
Holders Change %
-3.68%
% of All Funds
2.06%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
16
Increased
33
Reduced
52
Closed
21
Calls
$362​K
Puts
–
Net Calls
+$362​K
Net Calls Change
-⁠$1.15​M

ANAB Hedge Fund Activity: Q1 2022 in Review

131 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2022, worth a combined $736M — down 24% from $964M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ANAB and 16 opened new positions — a net loss of 5 holders — while 52 trimmed existing stakes and 33 added.

The largest buyer was Point72 Asset Management, adding an estimated $32.1M. The largest seller was Natixis, cutting an estimated $4.32M.

  • 131 institutional investors held AnaptysBio (ANAB) as of Q1 2022, down from 136 in Q4 2021.
  • Funds reported $736M of AnaptysBio stock for Q1 2022, down 24% quarter-over-quarter.
  • 16 funds opened new AnaptysBio positions in Q1 2022 and 21 closed out, a net change of -5 holders.
  • The largest AnaptysBio buyer in Q1 2022 was Point72 Asset Management, an estimated $32.1M added.
  • The largest AnaptysBio seller in Q1 2022 was Natixis, an estimated $4.32M sold.

Based on aggregated 13F filings for Q1 2022.